Pfizer halts Paxlovid trial for standard-risk patients

Pfizer-BioNTech will stop adding patients to its Paxlovid phase 2/3 trial after failing to prove the antiviral treatment reduced the relative risk of contracting COVID-19. 

Read the full post at Becker's Hospital Review - Healthcare News
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive